161 related articles for article (PubMed ID: 21478429)
1. Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway.
Bueno MJ; Gómez de Cedrón M; Gómez-López G; Pérez de Castro I; Di Lisio L; Montes-Moreno S; Martínez N; Guerrero M; Sánchez-Martínez R; Santos J; Pisano DG; Piris MA; Fernández-Piqueras J; Malumbres M
Blood; 2011 Jun; 117(23):6255-66. PubMed ID: 21478429
[TBL] [Abstract][Full Text] [Related]
2. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
Sander S; Bullinger L; Klapproth K; Fiedler K; Kestler HA; Barth TF; Möller P; Stilgenbauer S; Pollack JR; Wirth T
Blood; 2008 Nov; 112(10):4202-12. PubMed ID: 18713946
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
4. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
5. Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.
Oduor CI; Kaymaz Y; Chelimo K; Otieno JA; Ong'echa JM; Moormann AM; Bailey JA
BMC Cancer; 2017 Nov; 17(1):761. PubMed ID: 29132323
[TBL] [Abstract][Full Text] [Related]
6. Identification and analysis of the regulatory network of Myc and microRNAs from high-throughput experimental data.
Xiong L; Jiang W; Zhou R; Mao C; Guo Z
Comput Biol Med; 2013 Sep; 43(9):1252-60. PubMed ID: 23930820
[TBL] [Abstract][Full Text] [Related]
7. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
8. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Karkhanis V; Alinari L; Ozer HG; Chung J; Zhang X; Sif S; Baiocchi RA
J Biol Chem; 2020 Jan; 295(5):1165-1180. PubMed ID: 31822509
[TBL] [Abstract][Full Text] [Related]
9. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.
Ott G; Rosenwald A; Campo E
Hematology Am Soc Hematol Educ Program; 2013; 2013():575-83. PubMed ID: 24319234
[TBL] [Abstract][Full Text] [Related]
10. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
11. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1.
Craig VJ; Cogliatti SB; Imig J; Renner C; Neuenschwander S; Rehrauer H; Schlapbach R; Dirnhofer S; Tzankov A; Müller A
Blood; 2011 Jun; 117(23):6227-36. PubMed ID: 21460242
[TBL] [Abstract][Full Text] [Related]
12. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
[TBL] [Abstract][Full Text] [Related]
13. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.
D'Andrea A; Gritti I; Nicoli P; Giorgio M; Doni M; Conti A; Bianchi V; Casoli L; Sabò A; Mironov A; Beznoussenko GV; Amati B
Oncotarget; 2016 Nov; 7(45):72415-72430. PubMed ID: 27635472
[TBL] [Abstract][Full Text] [Related]
14. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer.
Benassi B; Flavin R; Marchionni L; Zanata S; Pan Y; Chowdhury D; Marani M; Strano S; Muti P; Blandino G; Loda M
Cancer Discov; 2012 Mar; 2(3):236-47. PubMed ID: 22585994
[TBL] [Abstract][Full Text] [Related]
15. Altered c-myc RNA metabolism in Burkitt's lymphomas and mouse plasmacytomas.
Piechaczyk M; Bonnieu A; Eick D; Remmers E; Yang JQ; Marcu K; Jeanteur P; Blanchard JM
Curr Top Microbiol Immunol; 1986; 132():331-8. PubMed ID: 3024921
[No Abstract] [Full Text] [Related]
16. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
[TBL] [Abstract][Full Text] [Related]
17. c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies.
Tao J; Zhao X; Tao J
Cell Cycle; 2014; 13(2):191-8. PubMed ID: 24394940
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
19. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
[TBL] [Abstract][Full Text] [Related]
20. Intricate crosstalk between MYC and non-coding RNAs regulates hallmarks of cancer.
Swier LJYM; Dzikiewicz-Krawczyk A; Winkle M; van den Berg A; Kluiver J
Mol Oncol; 2019 Jan; 13(1):26-45. PubMed ID: 30451365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
